| Description | Sialylglycopeptide is a complex N-glycan, bearing a short peptide fragment. Sialylglycopeptide, as a starting material for the semi-synthesis of N-glycans, can be used for various researches[1] | α-CGRP (human) (Calcitonin gene-related peptide) is a regulatory neuropeptide of 37 amino acids. α-CGRP (human) is widely distributed in the central and peripheral nervous system. α-CGRP (human) is a potent vasodilator and has inotropic and chronotropic effects[1][2][3] | Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosisBulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research[1][2]... Read More | Endomorphin 2 TFA, a high affinity, highly selective agonist of the µ-opioid receptor, displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM[1] | MOG (35-55) (MOG (35-55)) TFA is a minor component of CNS myelin. MOG (35-55) (TFA) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (TFA) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (TFA) produces a relapsing-MOG (35-55) (MOG (35-55)) TFA is a minor component of CNS myelin. MOG (35-55) (TFA) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (TFA) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (TFA) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (MOG (35-55)) TFA can be used for experimental autoimmune encephalomyelitis (EAE) modeling[1][2][3]... Read More |